Microsoft Corporation (MSFT)
Latest news, insights and market data
Market Data
AI Insights
No news
Latest News
| Title | Published |
|---|---|
AI Made Execution Easier. It Also Changed the Founder’s Most Important Job. AI Made Execution Easier. It Also Changed the Founder’s Most Important Job. | about 5 hours ago |
The Stock Market's Biggest Companies Are Losing Their Grip. Here's the ETF I'd Buy If History Repeats. As the market rotates away from large-cap stocks, new opportunities have emerged in their place. | about 9 hours ago |
1 Year Into the Microsoft Deal, IREN Is Delivering and a Rally May Follow Soon 1 Year Into the Microsoft Deal, IREN Is Delivering and a Rally May Follow Soon | about 9 hours ago |
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI | about 9 hours ago |
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated... | about 9 hours ago |
IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning | about 10 hours ago |
IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning IBM has raised its dividend for three decades straight, but the latest increase fits on a penny. Before counting on that income to keep pace with rising costs, retirees should understand what the streak actually delivers. | about 10 hours ago |
AI Made Execution Easier. It Also Changed the Founder’s Most Important Job.
AI Made Execution Easier. It Also Changed the Founder’s Most Important Job.
The Stock Market's Biggest Companies Are Losing Their Grip. Here's the ETF I'd Buy If History Repeats.
As the market rotates away from large-cap stocks, new opportunities have emerged in their place.
1 Year Into the Microsoft Deal, IREN Is Delivering and a Rally May Follow Soon
1 Year Into the Microsoft Deal, IREN Is Delivering and a Rally May Follow Soon
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...
IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning
IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning
IBM Has Raised Its Dividend for 31 Years. Inflation Is Still Winning
IBM has raised its dividend for three decades straight, but the latest increase fits on a penny. Before counting on that income to keep pace with rising costs, retirees should understand what the streak actually delivers.